{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T07:27:36Z","timestamp":1761290856246},"reference-count":25,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T00:00:00Z","timestamp":1083369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":5715,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2004,5]]},"DOI":"10.1093\/annonc\/mdh172","type":"journal-article","created":{"date-parts":[[2004,4,26]],"date-time":"2004-04-26T14:53:19Z","timestamp":1082991199000},"page":"770-774","source":"Crossref","is-referenced-by-count":51,"title":["Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience"],"prefix":"10.1016","volume":"15","author":[{"given":"J.J.","family":"Knox","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Hedley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Oza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.L.","family":"Siu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.R.","family":"Pond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.J.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdh172_bb0010","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1097\/00000658-198205000-00012","article-title":"Is cancer of the gallbladder a curable lesion?","volume":"195","author":"Wanebo","year":"1982","journal-title":"Ann Surg"},{"key":"10.1093\/annonc\/mdh172_bb0015","first-page":"415","article-title":"Primary carcinoma of the gallbladder: operative experience during a 16-year period","volume":"159","author":"Oertli","year":"1993","journal-title":"Eur J Surg"},{"key":"10.1093\/annonc\/mdh172_bb0020","first-page":"503","article-title":"Biliary carcinoma","volume":"147","author":"Alexander","year":"1984","journal-title":"A review of 109 cases. Am J Surg"},{"key":"10.1093\/annonc\/mdh172_bb0025","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/(SICI)1096-9098(199703)64:3<242::AID-JSO12>3.0.CO;2-6","article-title":"Experience with distal bile duct cancers in US veterans affairs hospitals: 1987\u20131991","volume":"64","author":"Wade","year":"1997","journal-title":"J Surg Oncol"},{"key":"10.1093\/annonc\/mdh172_bb0030","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/1097-0142(19840915)54:6<965::AID-CNCR2820540603>3.0.CO;2-X","article-title":"Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer","volume":"54","author":"Falkson","year":"1984","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdh172_bb0035","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1159\/000227373","article-title":"Combination of 5-fluorouracil, doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic\u2013biliary carcinomas","volume":"51","author":"Takada","year":"1994","journal-title":"Oncology"},{"key":"10.1093\/annonc\/mdh172_bb0040","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/00000421-199406000-00008","article-title":"Epirubicin-sequential methotrexate\u20135-fluorouracil\u2013leucovorin treatment in advanced cancer of the extrahepatic biliary system. A phase II study","volume":"17","author":"Kajanti","year":"1994","journal-title":"Am J Clin Oncol"},{"key":"10.1093\/annonc\/mdh172_bb0045","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/oxfordjournals.annonc.a010676","article-title":"Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer","volume":"7","author":"Glimelius","year":"1996","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdh172_bb0050","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1093\/annonc\/mdf201","article-title":"optimization of 5-fluorouracil (5-FU)\/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma","volume":"13","author":"Ta\u00efeb","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdh172_bb0055","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1002\/(SICI)1097-0142(19980615)82:12<2321::AID-CNCR4>3.0.CO;2-V","article-title":"A phase II trial of 5-FU leucovorin and carboplatin in patients with unresectable biliary tree carcinoma","volume":"82","author":"Sanz-Altamira","year":"1998","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdh172_bb0060","first-page":"3375","article-title":"Phase II trial of cisplatin, interferon \u03b1-2b, doxorubicin, and fluorouracil for biliary tract cancer","volume":"7","author":"Patt","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdh172_bb0065","first-page":"273","article-title":"Gemcitabine and cisplatin in the treatment of patients with unresectable or metastatic gallbladder cancer: results of the phase II Gocchi study 2000-13","volume":"22","author":"Reyes-Vidal","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdh172_bb0070","first-page":"280","article-title":"Multicenter phase II trial of oxaliplatin plus capecitabine (XELOX) in advanced biliary system adenocarcinomas (study CCC\/GBC-01)","volume":"22","author":"Nehls","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdh172_bb0075","first-page":"175a","article-title":"A randomized phase II trial of weekly high dose 5-FU (HD-FU) with and without folinic acid (FA) and cisplatin (P) in patients with advanced biliary tract carcinoma the EORTC 40955 trial","volume":"21","author":"Mitry","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdh172_bb0080","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000011961","article-title":"Two consecutive phase II studies of 5-FU\/leucovorin\/mitomycin and of gemcitabine in patients with advanced biliary cancer","volume":"56","author":"Raderer","year":"1999","journal-title":"Oncology"},{"key":"10.1093\/annonc\/mdh172_bb0085","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1023\/A:1012543223020","article-title":"A phase II study of gemcitabine in gallbladder carcinoma","volume":"12","author":"Gallardo","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdh172_bb0090","first-page":"264a","article-title":"Phase II trial of a weekly 150-minute gemcitabine infusion in patients with biliary tree carcinomas","volume":"19","author":"Dragovich","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdh172_bb0095","first-page":"783","article-title":"A phase II study of gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas","volume":"48","author":"Kubicka","year":"2001","journal-title":"Hepatogastroenterology"},{"key":"10.1093\/annonc\/mdh172_bb0100","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1023\/A:1008352123009","article-title":"Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer","volume":"12","author":"Penz","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdh172_bb0105","first-page":"251a","article-title":"Synergistic interaction of gemcitabine and 5-fluorouracil in colon cancer cells","volume":"17","author":"Schulz","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdh172_bb0110","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1200\/JCO.1999.17.2.585","article-title":"Phase I\u2013II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer","volume":"17","author":"Hidalgo","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh172_bb0115","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1200\/JCO.2001.19.20.4089","article-title":"Treatment of inoperable and\/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study","volume":"10","author":"Gebbia","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh172_bb0120","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1200\/JCO.2002.11.135","article-title":"Complication rates among cancer patients with peripherally inserted central catheters","volume":"20","author":"Walshe","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh172_bb0125","first-page":"264a","article-title":"Oral capecitabine (Xeloda) for the treatment of hepatobiliary cancers (hepatocellular carcinoma, cholangiocarcinoma and gallbladder cancer)","volume":"19","author":"Lozano","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdh172_bb0130","first-page":"S17","article-title":"Phase III trial comparing epirubivin, cisplatin and 5-FU (ECF) versus 5FU, etoposide and leucovorin (FELV) in previously untreated patients with advanced biliary cancer","volume":"12","author":"Rao","year":"2003","journal-title":"Proc Eur Cancer Conf (ECCO 12)"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419557714?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419557714?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/15\/5\/770\/463004\/mdh172.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T17:54:01Z","timestamp":1582221241000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419557714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,5]]}},"alternative-id":["S0923753419557714"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdh172","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2004,5]]}}}